Skip to content
Acting Auditions – Lifestyle
Author:
HCW Biologics Inc.
HCW Biologics Reports Third Quarter 2026 Business and Clinical Development Highlights and Financial Results
November 16, 2026
HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company’s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer’s 41st Annual Meeting
November 9, 2026
HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer
November 6, 2026
HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
November 5, 2026
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
October 9, 2026
HCW Biologics Announces Pricing of $1.5 Million Private Placement
September 24, 2026
HCW11-006 CAR-T Reagent Commercialized by HCW Biologics & Akron Biotech
September 8, 2026
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
September 2, 2026
Technical College System of Georgia Launches Statewide Partnership for Mental Health Support
August 21, 2026
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
August 14, 2026
1
2
Next Page
→